TrialDiabetes, obesity & metabolism2026

Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.

Sean Wharton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.